首页> 美国卫生研究院文献>American Journal of Translational Research >The efficacy of cisplatin and low-temperature plasma radiofrequency ablation in advanced laryngeal cancer patients and on the serum survivin levels
【2h】

The efficacy of cisplatin and low-temperature plasma radiofrequency ablation in advanced laryngeal cancer patients and on the serum survivin levels

机译:顺铂和低温血浆射频消融在晚期喉癌患者中的疗效和血清Survivin水平

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: To investigate the effect of cisplatin injections combined with low-temperature plasma radiofrequency ablation on the clinical efficacy and serum survivin levels in advanced laryngeal cancer patients. Methods: A total of 42 patients with locally advanced laryngeal cancer treated in our hospital from January 2018 to June 2020 were recruited as the study cohort and placed in a control group (21 cases) or a treatment group (21 cases) according to the medication administered to each patient. The patients in the control group were treated with CO2 laser resections under laryngoscopy combined with cisplatin injections, and the patients in the observation group were treated with low-temperature plasma radiofrequency ablation combined with cisplatin injections. The clinical efficacies in the two groups were observed and the WHOQOL-BREF scores, tumor marker levels, and serum survivin levels were compared. Results: After the treatment, the ORR and CBR in the control group were 33.3% and 61.9%, respectively, levels that were significantly lower than the 66.7% and 90.5% in the observation group (P<0.05). The observation group’s physiological, psychological, and social relations dimension scores were significantly higher than the corresponding scores in the control group (P<0.05). The tumor markers in the observation group were significantly lower in the serum CA72-4, CA19-9, and SCC-Ag levels than they were in the control group (P<0.05). The observation group exhibited lower serum survivin levels than the control group (P<0.05). Conclusion Cisplatin injections combined with low-temperature plasma radiofrequency ablation has a significant effect on the treatment of locally advanced laryngeal cancer. It can improve patients’ quality of life, reduce the tumor marker levels in the body, and inhibit the serum survivin levels.
机译:目的:探讨顺铂注射液结合低温血浆射频消融对晚期喉癌患者临床疗效和血清存活素水平的影响。方法:2018年1月至6月20日至6月至6月份的42例患有本地晚期喉癌的患者被招募为研究队列,并根据药物治疗组(21例)或治疗组(21例)给每位患者施用。对照组的患者用CISplatin注射的CISPRATIN注射液下的CO2激光切除治疗,并用低温血浆射频消融治疗观察组的患者,结合顺铂喷射。观察到两组的临床疗效,比较了WHOQol-BREF得分,肿瘤标志物水平和血清Survivin水平。结果:治疗后,对照组的ORR和CBR分别为33.3%和61.9%,分别低于观察组的66.7%和90.5%(P <0.05)。观察组的生理学,心理和社会关系维度分数明显高于对照组的相应评分(P <0.05)。观察组中的肿瘤标志物在血清CA72-4,CA19-9和SCC-AG水平中显着降低,而不是对照组(P <0.05)。观察组表现出比对照组更低的血清Survivin水平(P <0.05)。结论顺铂注射结合低温血浆射频消融对局部晚期喉癌的治疗具有显着影响。它可以改善患者的生活质量,减少体内肿瘤标志物水平,并抑制血清存活素水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号